Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor
October 21, 2019 – The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's...
Videos | Antiplatelet and Anticoagulation Therapies | October 17, 2019
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional...
Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019
October 16, 2019 — Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay...
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 10, 2019
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., interventional cardiologist and the Arthur L. Bloomfield...
Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT
News | Stents Drug Eluting | September 30, 2019
September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug-...
Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD
News | Stents Drug Eluting | September 30, 2019
September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
September 30, 2019 – Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
September 26, 2019 — New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy...
Aspirin Should Not Be Recommended for Healthy People Over 70
News | Antiplatelet and Anticoagulation Therapies | September 20, 2019
September 20, 2019 — Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in...
FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
September 18, 2019 — AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
September 11, 2019 — The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint...
Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
September 10,2019 — The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in...
Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients
News | Antiplatelet and Anticoagulation Therapies | September 09, 2019
September 9, 2019 — Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary...